Pub Date : 2026-02-03DOI: 10.1038/s41591-025-04193-6
Richard S. Finkel, Thomas O. Crawford, Eugenio Mercuri, Charlotte J. Sumner, Maria del Mar Garcia Romero, John W. Day, Jacqueline Montes, Peng Sun, Ben Tichler, Angela D. Paradis, Emily Boesch, Jennifer Inra, Ross Littauer, Jihee Sohn, Michael Monine, Giulia Gambino, Richard Foster, Raechel Farewell, Stephanie Fradette
Despite the remarkable benefits of nusinersen and other disease-modifying therapies in spinal muscular atrophy (SMA), patients may still experience clinical manifestations of the disease. Here we assessed the potential for high-dose nusinersen to rapidly slow neurodegeneration and lead to improved outcomes for patients. The global, three-part, phase 2/3 DEVOTE trial evaluated the efficacy and safety of high-dose nusinersen (50-mg loading dose; 28-mg maintenance dose) in individuals with SMA. In Part B, treatment-naive individuals (n = 75) were randomized 2:1 to 50/28 mg or 12/12 mg nusinersen. In a supportive open-label cohort (Part C), nusinersen-experienced individuals (12/12 mg for more than 1 year) were enrolled. The primary endpoint (Part B infantile-onset participants) was a 6-month change in the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) total score comparing 50/28 mg with matched ENDEAR participants (n = 20) who received sham. DEVOTE met its primary endpoint: at day 183, the CHOP-INTEND total score significantly improved (+15.1 points) in those who received 50/28 mg nusinersen and worsened (−11.1 points) in matched ENDEAR participants who received sham (difference, 26.19 (95% confidence interval = 20.7 to 31.74); statistical testing was performed using the joint-rank test where the difference in ranks was 26.06 (95% confidence interval = 17.9 to 34.2; P < 0.0001). The safety profile of 50/28 mg nusinersen was similar to the 12/12 mg regimen. The data support that high-dose nusinersen provides benefit in patients with SMA, with a generally well-tolerated safety profile. ClinicalTrials.gov registration: https://clinicaltrials.gov/study/NCT04089566. EudraCT no: 2019-002663-10.
{"title":"High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial","authors":"Richard S. Finkel, Thomas O. Crawford, Eugenio Mercuri, Charlotte J. Sumner, Maria del Mar Garcia Romero, John W. Day, Jacqueline Montes, Peng Sun, Ben Tichler, Angela D. Paradis, Emily Boesch, Jennifer Inra, Ross Littauer, Jihee Sohn, Michael Monine, Giulia Gambino, Richard Foster, Raechel Farewell, Stephanie Fradette","doi":"10.1038/s41591-025-04193-6","DOIUrl":"https://doi.org/10.1038/s41591-025-04193-6","url":null,"abstract":"Despite the remarkable benefits of nusinersen and other disease-modifying therapies in spinal muscular atrophy (SMA), patients may still experience clinical manifestations of the disease. Here we assessed the potential for high-dose nusinersen to rapidly slow neurodegeneration and lead to improved outcomes for patients. The global, three-part, phase 2/3 DEVOTE trial evaluated the efficacy and safety of high-dose nusinersen (50-mg loading dose; 28-mg maintenance dose) in individuals with SMA. In Part B, treatment-naive individuals (n = 75) were randomized 2:1 to 50/28 mg or 12/12 mg nusinersen. In a supportive open-label cohort (Part C), nusinersen-experienced individuals (12/12 mg for more than 1 year) were enrolled. The primary endpoint (Part B infantile-onset participants) was a 6-month change in the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) total score comparing 50/28 mg with matched ENDEAR participants (n = 20) who received sham. DEVOTE met its primary endpoint: at day 183, the CHOP-INTEND total score significantly improved (+15.1 points) in those who received 50/28 mg nusinersen and worsened (−11.1 points) in matched ENDEAR participants who received sham (difference, 26.19 (95% confidence interval = 20.7 to 31.74); statistical testing was performed using the joint-rank test where the difference in ranks was 26.06 (95% confidence interval = 17.9 to 34.2; P < 0.0001). The safety profile of 50/28 mg nusinersen was similar to the 12/12 mg regimen. The data support that high-dose nusinersen provides benefit in patients with SMA, with a generally well-tolerated safety profile. ClinicalTrials.gov registration: https://clinicaltrials.gov/study/NCT04089566. EudraCT no: 2019-002663-10.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"1 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146102152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-03DOI: 10.1038/s41591-025-04184-7
Michelle M Li, Ben Y Reis, Adam Rodman, Tianxi Cai, Noa Dagan, Ran D Balicer, Joseph Loscalzo, Isaac S Kohane, Marinka Zitnik
Medical artificial intelligence (AI) tools, including clinical language models, vision-language models and multimodal health record models, are used to summarize clinical notes, answer questions and support decisions. Their adaptation to new populations, specialties or care settings often relies on fine-tuning, prompting or retrieval from external knowledge bases. These strategies can scale poorly and risk contextual errors-outputs that appear plausible but miss critical patient or situational information. We envision context switching as an emergent solution. Context switching adjusts model reasoning at inference, without retraining. Generative models can tailor outputs to patient biology, care setting or disease. Multimodal models can switch between notes, laboratory results, imaging and genomics, even when some data are missing or delayed. Agent models can coordinate tools and roles based on task and user context. In each case, context switching enables medical AI to adapt across specialties, populations and geographies. This approach requires advances in data design, model architectures and evaluation frameworks, and establishes a foundation for medical AI that scales to an infinite number of contexts, while remaining reliable and suited to real-world care.
{"title":"Scaling medical AI across clinical contexts.","authors":"Michelle M Li, Ben Y Reis, Adam Rodman, Tianxi Cai, Noa Dagan, Ran D Balicer, Joseph Loscalzo, Isaac S Kohane, Marinka Zitnik","doi":"10.1038/s41591-025-04184-7","DOIUrl":"https://doi.org/10.1038/s41591-025-04184-7","url":null,"abstract":"<p><p>Medical artificial intelligence (AI) tools, including clinical language models, vision-language models and multimodal health record models, are used to summarize clinical notes, answer questions and support decisions. Their adaptation to new populations, specialties or care settings often relies on fine-tuning, prompting or retrieval from external knowledge bases. These strategies can scale poorly and risk contextual errors-outputs that appear plausible but miss critical patient or situational information. We envision context switching as an emergent solution. Context switching adjusts model reasoning at inference, without retraining. Generative models can tailor outputs to patient biology, care setting or disease. Multimodal models can switch between notes, laboratory results, imaging and genomics, even when some data are missing or delayed. Agent models can coordinate tools and roles based on task and user context. In each case, context switching enables medical AI to adapt across specialties, populations and geographies. This approach requires advances in data design, model architectures and evaluation frameworks, and establishes a foundation for medical AI that scales to an infinite number of contexts, while remaining reliable and suited to real-world care.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":" ","pages":""},"PeriodicalIF":50.0,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146113699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-03DOI: 10.1038/s41591-026-04199-8
Paul Adepoju
{"title":"Fault lines in a global promise.","authors":"Paul Adepoju","doi":"10.1038/s41591-026-04199-8","DOIUrl":"https://doi.org/10.1038/s41591-026-04199-8","url":null,"abstract":"","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":" ","pages":""},"PeriodicalIF":50.0,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146113586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-02DOI: 10.1038/s41591-026-04200-4
{"title":"Integration of health check-ups into school and healthcare systems can improve adolescent health in LMICs.","authors":"","doi":"10.1038/s41591-026-04200-4","DOIUrl":"https://doi.org/10.1038/s41591-026-04200-4","url":null,"abstract":"","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":" ","pages":""},"PeriodicalIF":50.0,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146106303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-02DOI: 10.1038/s41591-025-04156-x
Aoife M. Doyle, Farirai Nzvere, Salome Manyau, Victoria Simms, Ines Li Lin, Faith R. Kandiye, Chipo Ashley Nyamayaro, Michaela Takawira, Rudo M. S. Chingono, Mandikudza Tembo, Ronald Manhibi, Ethel Dauya, Chido Dziva Chikwari, Giulia Greco, Sarah Bernays, Valentina Baltag, Hannah Maisiri, Tonderai Kasu, Wenceslas Nyamayaro, Tsitsi Bandason, Constance R. S. Mackworth-Young, Prerna Banati, Helen A. Weiss, David A. Ross, Rashida A. Ferrand
Routine adolescent health check-ups can support healthy development and well-being, but evidence on the feasibility, acceptability and effectiveness of contextually relevant comprehensive check-ups in low- and middle-income settings is limited. We conducted a hybrid implementation-effectiveness study incorporating a mixed-methods pre−post design of Y-Check, a comprehensive health check-up intervention in Zimbabwe, as part of a multicountry study developed and coordinated by the World Health Organization. Eligible participants were 10–19-year-old adolescents attending school or community venues. We used self-administered digital questionnaires, provider-led clinical tests and nurse reviews to screen for 25 conditions/behaviors. We provided health promotion, on-site care and referral to relevant providers. From October 2022 to September 2023, 2,097 adolescents were enrolled, of whom 1,843 (87.9%) were seen at 6 months. The primary outcome of appropriate care and/or referral(s) for all identified issues was achieved for 70.8% (95% confidence interval: 68.7–72.9%) of 1,865 participants with at least one issue. At follow-up, there were improvements in nutrition, health-related quality of life, self-esteem, behaviors and educational outcomes. The intervention was feasible and largely acceptable. Uptake of referral services varied by issue. Y-Check cost US$47 per participant. Through Y-Check, we identified untreated conditions and risk behaviors and successfully treated and linked adolescents to services. Here we provide evidence on the potential of the intervention to positively impact health and well-being.
{"title":"Implementation and evaluation of the Y-Check comprehensive adolescent health check-up intervention in Zimbabwe: a pre−post mixed-methods study","authors":"Aoife M. Doyle, Farirai Nzvere, Salome Manyau, Victoria Simms, Ines Li Lin, Faith R. Kandiye, Chipo Ashley Nyamayaro, Michaela Takawira, Rudo M. S. Chingono, Mandikudza Tembo, Ronald Manhibi, Ethel Dauya, Chido Dziva Chikwari, Giulia Greco, Sarah Bernays, Valentina Baltag, Hannah Maisiri, Tonderai Kasu, Wenceslas Nyamayaro, Tsitsi Bandason, Constance R. S. Mackworth-Young, Prerna Banati, Helen A. Weiss, David A. Ross, Rashida A. Ferrand","doi":"10.1038/s41591-025-04156-x","DOIUrl":"https://doi.org/10.1038/s41591-025-04156-x","url":null,"abstract":"Routine adolescent health check-ups can support healthy development and well-being, but evidence on the feasibility, acceptability and effectiveness of contextually relevant comprehensive check-ups in low- and middle-income settings is limited. We conducted a hybrid implementation-effectiveness study incorporating a mixed-methods pre−post design of Y-Check, a comprehensive health check-up intervention in Zimbabwe, as part of a multicountry study developed and coordinated by the World Health Organization. Eligible participants were 10–19-year-old adolescents attending school or community venues. We used self-administered digital questionnaires, provider-led clinical tests and nurse reviews to screen for 25 conditions/behaviors. We provided health promotion, on-site care and referral to relevant providers. From October 2022 to September 2023, 2,097 adolescents were enrolled, of whom 1,843 (87.9%) were seen at 6 months. The primary outcome of appropriate care and/or referral(s) for all identified issues was achieved for 70.8% (95% confidence interval: 68.7–72.9%) of 1,865 participants with at least one issue. At follow-up, there were improvements in nutrition, health-related quality of life, self-esteem, behaviors and educational outcomes. The intervention was feasible and largely acceptable. Uptake of referral services varied by issue. Y-Check cost US$47 per participant. Through Y-Check, we identified untreated conditions and risk behaviors and successfully treated and linked adolescents to services. Here we provide evidence on the potential of the intervention to positively impact health and well-being.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"87 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146102154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-02DOI: 10.1038/s41591-025-04181-w
Zhe Huang, Liang Zeng, Zhaohui Ruan, Qun Zeng, Huan Yan, Wenjuan Jiang, Yi Xiong, Chunhua Zhou, Haiyan Yang, Li Liu, Jiacheng Dai, Nachuan Zou, Shidong Xu, Ya Wang, Zhan Wang, Jun Deng, Xue Chen, Jing Wang, Hua Xiang, Xiaomei Li, Boris Duchemann, Guoqiang Chen, Yang Xia, Tony Mok, Christoph Scheiermann, Francis Lévi, Nong Yang, Yongchang Zhang
Retrospective studies suggest that early time-of-day (ToD) infusions of immunochemotherapy may improve efficacy. However, prospective randomized controlled trials are needed to validate it. In this randomized phase 3 LungTIME-C01 trial, 210 patients with treatment naive stage IIIC–IV nonsmall cell lung cancer (NSCLC) lacking driver mutations were randomly assigned in a 1:1 ratio to either an early or late ToD group, defined by the administration of the first four cycles of an anti-PD-1 agent before or after 15:00 h. The primary endpoint was progression-free survival (PFS), while secondary endpoints included overall survival (OS) and objective response rate (ORR). After a median follow-up of 28.7 months, the median PFS was 11.3 months (95% confidence interval (CI) = 9.2–13.4) in the early ToD group and 5.7 months (95% CI = 5.2–6.2) in the late ToD group, corresponding to a hazard ratio (HR) for earlier disease progression of 0.40 (95% CI = 0.29–0.55; P < 0.001). The median OS was 28.0 months (95% CI = not estimable (NE)–NE) in the early ToD group and 16.8 months (95% CI = 13.7–19.9) in the late ToD group, corresponding to an HR of an earlier death of 0.42 (95% CI = 0.29–0.60; P < 0.001). Treatment-related adverse events were consistent with the established safety profile, with no new safety signals observed. No significant differences in immune-related adverse events were observed between the two groups. Over the first four cycles, morning circulating CD8+ T cells increased in the early ToD group, whereas they declined in the late ToD group (P < 0.001). Furthermore, the ratio of activated (CD38+ HLA-DR+) versus exhausted (TIM-3+PD-1+) CD8+ T cells was higher in the early ToD group (P < 0.001) compared with the late ToD group (P < 0.001). In summary, our study indicates that early ToD immunochemotherapy substantially improves PFS and OS and is associated with enhanced antitumor CD8+ T cell characteristics compared with late ToD treatment. ClinicalTrials.gov registration: NCT05549037.
回顾性研究表明，每天早时间（ToD）输注免疫化疗可提高疗效。然而，需要前瞻性随机对照试验来验证它。在这项随机的3期临床试验中，210例缺乏驱动突变的初始IIIC-IV期非小细胞肺癌（NSCLC）患者被按1:1的比例随机分配到早期或晚期ToD组，通过在15:00之前或之后施用抗pd -1药物的前四个周期来定义。主要终点是无进展生存期（PFS），次要终点包括总生存期（OS）和客观缓解率（ORR）。中位随访28.7个月后，ToD早期组的中位PFS为11.3个月（95%可信区间(CI) = 9.2-13.4）， ToD晚期组的中位PFS为5.7个月（95% CI = 5.2-6.2），对应于早期疾病进展的风险比（HR）为0.40 （95% CI = 0.29-0.55; P < 0.001）。ToD早期组的中位OS为28.0个月（95% CI =不可估计(NE) -NE）， ToD晚期组的中位OS为16.8个月（95% CI = 13.7-19.9），对应于早期死亡的HR为0.42 （95% CI = 0.29-0.60; P < 0.001）。与治疗相关的不良事件与既定的安全性一致，未观察到新的安全性信号。两组之间免疫相关不良事件无显著差异。在前四个周期中，ToD早期组的晨循环CD8+ T细胞增加，而ToD晚期组的晨循环CD8+ T细胞减少（P < 0.001）。此外，与ToD晚期组相比，ToD早期组活化（CD38+ HLA-DR+）和耗尽（TIM-3+PD-1+） CD8+ T细胞的比例（P < 0.001）更高。综上所述，我们的研究表明，与晚期ToD治疗相比，早期ToD免疫化疗显著改善了PFS和OS，并与增强的抗肿瘤CD8+ T细胞特征相关。ClinicalTrials.gov注册：NCT05549037。
{"title":"Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial","authors":"Zhe Huang, Liang Zeng, Zhaohui Ruan, Qun Zeng, Huan Yan, Wenjuan Jiang, Yi Xiong, Chunhua Zhou, Haiyan Yang, Li Liu, Jiacheng Dai, Nachuan Zou, Shidong Xu, Ya Wang, Zhan Wang, Jun Deng, Xue Chen, Jing Wang, Hua Xiang, Xiaomei Li, Boris Duchemann, Guoqiang Chen, Yang Xia, Tony Mok, Christoph Scheiermann, Francis Lévi, Nong Yang, Yongchang Zhang","doi":"10.1038/s41591-025-04181-w","DOIUrl":"https://doi.org/10.1038/s41591-025-04181-w","url":null,"abstract":"Retrospective studies suggest that early time-of-day (ToD) infusions of immunochemotherapy may improve efficacy. However, prospective randomized controlled trials are needed to validate it. In this randomized phase 3 LungTIME-C01 trial, 210 patients with treatment naive stage IIIC–IV nonsmall cell lung cancer (NSCLC) lacking driver mutations were randomly assigned in a 1:1 ratio to either an early or late ToD group, defined by the administration of the first four cycles of an anti-PD-1 agent before or after 15:00 h. The primary endpoint was progression-free survival (PFS), while secondary endpoints included overall survival (OS) and objective response rate (ORR). After a median follow-up of 28.7 months, the median PFS was 11.3 months (95% confidence interval (CI) = 9.2–13.4) in the early ToD group and 5.7 months (95% CI = 5.2–6.2) in the late ToD group, corresponding to a hazard ratio (HR) for earlier disease progression of 0.40 (95% CI = 0.29–0.55; P < 0.001). The median OS was 28.0 months (95% CI = not estimable (NE)–NE) in the early ToD group and 16.8 months (95% CI = 13.7–19.9) in the late ToD group, corresponding to an HR of an earlier death of 0.42 (95% CI = 0.29–0.60; P < 0.001). Treatment-related adverse events were consistent with the established safety profile, with no new safety signals observed. No significant differences in immune-related adverse events were observed between the two groups. Over the first four cycles, morning circulating CD8+ T cells increased in the early ToD group, whereas they declined in the late ToD group (P < 0.001). Furthermore, the ratio of activated (CD38+ HLA-DR+) versus exhausted (TIM-3+PD-1+) CD8+ T cells was higher in the early ToD group (P < 0.001) compared with the late ToD group (P < 0.001). In summary, our study indicates that early ToD immunochemotherapy substantially improves PFS and OS and is associated with enhanced antitumor CD8+ T cell characteristics compared with late ToD treatment. ClinicalTrials.gov registration: NCT05549037.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"67 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146102153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-30DOI: 10.1038/d41591-026-00004-8
Karen O'Leary
{"title":"Base editing enables off-the-shelf CAR T cells for leukemia.","authors":"Karen O'Leary","doi":"10.1038/d41591-026-00004-8","DOIUrl":"https://doi.org/10.1038/d41591-026-00004-8","url":null,"abstract":"","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"37 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146089091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-30DOI: 10.1038/d41591-026-00005-7
Karen O'Leary
{"title":"New analysis shows no link between autism and paracetamol.","authors":"Karen O'Leary","doi":"10.1038/d41591-026-00005-7","DOIUrl":"https://doi.org/10.1038/d41591-026-00005-7","url":null,"abstract":"","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"3 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146089005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-29DOI: 10.1038/s41591-026-04234-8
Pawel K Mazur, Alexander Herner, Stephano S Mello, Matthias Wirth, Simone Hausmann, Francisco J Sánchez-Rivera, Shane M Lofgren, Timo Kuschma, Stephan A Hahn, Deepak Vangala, Marija Trajkovic-Arsic, Aayush Gupta, Irina Heid, Peter B Noël, Rickmer Braren, Mert Erkan, Jörg Kleeff, Bence Sipos, Leanne C Sayles, Mathias Heikenwalder, Elisabeth Heßmann, Volker Ellenrieder, Irene Esposito, Tyler Jacks, James E Bradner, Purvesh Khatri, E Alejandro Sweet-Cordero, Laura D Attardi, Roland M Schmid, Guenter Schneider, Julien Sage, Jens T Siveke
{"title":"Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.","authors":"Pawel K Mazur, Alexander Herner, Stephano S Mello, Matthias Wirth, Simone Hausmann, Francisco J Sánchez-Rivera, Shane M Lofgren, Timo Kuschma, Stephan A Hahn, Deepak Vangala, Marija Trajkovic-Arsic, Aayush Gupta, Irina Heid, Peter B Noël, Rickmer Braren, Mert Erkan, Jörg Kleeff, Bence Sipos, Leanne C Sayles, Mathias Heikenwalder, Elisabeth Heßmann, Volker Ellenrieder, Irene Esposito, Tyler Jacks, James E Bradner, Purvesh Khatri, E Alejandro Sweet-Cordero, Laura D Attardi, Roland M Schmid, Guenter Schneider, Julien Sage, Jens T Siveke","doi":"10.1038/s41591-026-04234-8","DOIUrl":"https://doi.org/10.1038/s41591-026-04234-8","url":null,"abstract":"","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":" ","pages":""},"PeriodicalIF":50.0,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146086482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：